Insider Transactions in Q1 2021 at Masimo Corp (MASI)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 22
2021
|
Micah W Young EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,593
+50.0%
|
-
|
|
Feb 22
2021
|
Yongsam Lee EVP, CIO |
BUY
Grant, award, or other acquisition
|
Direct |
14,593
+13.74%
|
-
|
|
Feb 22
2021
|
Jon Coleman Pres-WW OEM & Global Health |
BUY
Grant, award, or other acquisition
|
Direct |
14,593
+34.04%
|
-
|
|
Feb 22
2021
|
Thomas Samuel Mc Clenahan EVP, GEN COUNSEL & CORP SEC |
BUY
Grant, award, or other acquisition
|
Direct |
14,593
+39.8%
|
-
|
|
Feb 22
2021
|
Anand Sampath EVP, Ops & Clinical Research |
BUY
Grant, award, or other acquisition
|
Direct |
14,593
+33.03%
|
-
|
|
Feb 22
2021
|
Tao Levy EVP, BUS DEV |
BUY
Grant, award, or other acquisition
|
Direct |
14,593
+50.0%
|
-
|
|
Feb 22
2021
|
Bilal Muhsin Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,593
+50.0%
|
-
|
|
Feb 22
2021
|
Joe E Kiani CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
145,944
+30.98%
|
-
|
|
Jan 12
2021
|
Joe E Kiani CEO and Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
3,403
-4.06%
|
$952,840
$280.32 P/Share
|
|
Jan 11
2021
|
Craig B Reynolds Director |
SELL
Open market or private sale
|
Direct |
10,000
-69.93%
|
$2,790,000
$279.74 P/Share
|
|
Jan 11
2021
|
Craig B Reynolds Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+41.15%
|
$230,000
$23.04 P/Share
|
|
Jan 11
2021
|
Joe E Kiani CEO and Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
9,034
-9.73%
|
$2,529,520
$280.45 P/Share
|
|
Jan 08
2021
|
Joe E Kiani CEO and Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
52,698
-36.21%
|
$14,808,138
$281.93 P/Share
|
|
Jan 07
2021
|
Joe E Kiani CEO and Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
1,542
-1.05%
|
$431,760
$280.05 P/Share
|
|
Jan 02
2021
|
Anand Sampath EVP, Ops & Clinical Research |
SELL
Payment of exercise price or tax liability
|
Direct |
786
-4.98%
|
$210,648
$268.38 P/Share
|
|
Jan 02
2021
|
Anand Sampath EVP, Ops & Clinical Research |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+11.25%
|
-
|
|
Jan 02
2021
|
Thomas Samuel Mc Clenahan EVP, GEN COUNSEL & CORP SEC |
SELL
Payment of exercise price or tax liability
|
Direct |
786
-9.51%
|
$210,648
$268.38 P/Share
|
|
Jan 02
2021
|
Thomas Samuel Mc Clenahan EVP, GEN COUNSEL & CORP SEC |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+19.49%
|
-
|
|
Jan 02
2021
|
Joe E Kiani CEO and Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+10.04%
|
-
|
|
Jan 02
2021
|
Jon Coleman Pres-WW OEM & Global Health |
SELL
Payment of exercise price or tax liability
|
Direct |
786
-5.43%
|
$210,648
$268.38 P/Share
|
|
Jan 02
2021
|
Jon Coleman Pres-WW OEM & Global Health |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+12.15%
|
-
|
|
Jan 02
2021
|
Yongsam Lee EVP, CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+2.53%
|
-
|